Patrys Limited Stock price

Equities

PAB

AU000000PAB9

Biotechnology & Medical Research

Market Closed - Australian S.E. 11:14:15 2024-03-27 pm EDT 5-day change 1st Jan Change
0.009 AUD -10.00% Intraday chart for Patrys Limited 0.00% +12.50%
Sales 2022 3.33M 2.18M Sales 2023 2.85M 1.86M Capitalization 20.57M 13.43M
Net income 2022 -6M -3.92M Net income 2023 -7M -4.57M EV / Sales 2022 9.39 x
Net cash position 2022 9.82M 6.41M Net cash position 2023 4.05M 2.64M EV / Sales 2023 5.8 x
P/E ratio 2022
-5.78 x
P/E ratio 2023
-2.91 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 69.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day-10.00%
Current month-10.00%
1 month+12.50%
3 months+12.50%
6 months+28.57%
Current year+12.50%
More quotes
1 week
0.01
Extreme 0.009
0.01
1 month
0.01
Extreme 0.009
0.01
Current year
0.01
Extreme 0.007
0.01
1 year
0.01
Extreme 0.006
0.02
3 years
0.01
Extreme 0.006
0.06
5 years
0.01
Extreme 0.006
0.06
10 years
0.00
Extreme 0.004
0.08
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-11-11
Chief Tech/Sci/R&D Officer - 12-05-31
Corporate Officer/Principal - 22-05-15
Members of the board TitleAgeSince
Director/Board Member 63 19-09-30
Chief Executive Officer - 14-11-11
Director/Board Member - 07-02-18
More insiders
Date Price Change Volume
24-03-28 0.009 -10.00% 658,986
24-03-27 0.01 +11.11% 590,304
24-03-25 0.009 0.00% 748,514
24-03-21 0.009 -10.00% 2,868,777
24-03-20 0.01 0.00% 299,500

Delayed Quote Australian S.E., March 27, 2024 at 11:14 pm EDT

More quotes
Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.
More about the company
  1. Stock
  2. Equities
  3. Stock Patrys Limited - Australian S.E.